Management of Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory Disease
Talking abstract delivered by Dr Mark Arnold (Emory University School of Medicine, Atlanta, GA, USA) for the paper: Arnold M, Kuruvilla M and Levy JM. Management of Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory Disease. touchREVIEWS in Respiratory & Pulmonary Diseases. 2021;6(1):21–5.
Share this Video
Related Videos In Allergy
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Ozge Can Bostan, EAACI 2022: Low Dose Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Mepolizumab is currently approved for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300mg. touchRESPIRATORY caught up with Dr. Ozge Can Bostan (Hacettepe University School of Medicine, Ankara, Turkey) to discuss the 1 year findings from her study investigating the sinonasal and respiratory outcomes of a low dose of mepolizumab (100 […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!